Medtronic Contegra
This article was originally published in The Gray Sheet
Executive Summary
Pulmonary valved conduit receives FDA Humanitarian Device Exemption approval, firm announces Nov. 24. The bioprosthetic, composed of a bovine jugular vein containing an integral valve that can be used to reconstruct a blood pathway from the right ventricle to the lungs, corrects congenital defects of the right side of the heart in patients under 18. Contegra can be used instead of a human valve, supplies of which are limited, Medtronic notes. The company has been distributing the device outside the U.S. since 1998 and acquired the product from VenPro in 2001...
You may also be interested in...
FDA Assembling Advisors To Discuss Pediatric HDE Products
As part of a periodic review, FDA is bringing together experts to review several products that are conditionally available for pediatric use under the agency's Humanitarian Device Exemption program.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.